Inhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice

• Үндсэн зохиолчид: Marcos F. Fondevila (Зохиогч), Eva Novoa (Зохиогч), Uxia Fernandez (Зохиогч), Valentina Dorta (Зохиогч), Tamara Parracho (Зохиогч), Henriette Kreimeyer (Зохиогч), Maria Garcia-Vence (Зохиогч), Maria P. Chantada-Vazquez (Зохиогч), Susana B. Bravo (Зохиогч), Begoña Porteiro (Зохиогч), Alba Cabaleiro (Зохиогч), Mijra Koning (Зохиогч), Ana Senra (Зохиогч), Yara Souto (Зохиогч), Joanne Verheij (Зохиогч), Diana Guallar (Зохиогч), Miguel Fidalgo (Зохиогч), Abraham S. Meijnikman (Зохиогч), Natalia da Silva Lima (Зохиогч), Carlos Dieguez (Зохиогч), Maria J. Gonzalez-Rellan (Зохиогч), Ruben Nogueiras (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Elsevier, 2024-07-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Objective: p63 is a transcription factor involved in multiple biological functions. In the liver, the TAp63 isoform induces lipid accumulation in hepatocytes. However, the role of liver TAp63 in the progression of metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis is unknown. Meth...